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Postprandial Hypoglycemia: An Unusual Presentation for 
Insulinoma
Postprandiyal Hipoglisemi: İnsülinoma için Sıradışı Bir Prezentasyon
Abs tract
Öz
Introduction
Insulinoma is the most common type of islet cell tumor of the 
pancreas and its incidence is estimated at four per one million 
persons per year (1). It may occur at any age and does not show 
gender predominance. Only 10% of insulinomas have been 
reported to be malignant, while the only criterion for malignancy 
is the presence of metastases (2). Although fasting hypoglycemia 
is the typical presentation, cases with postprandial hypoglycemia 
have rarely been reported (3,4). Surgical resection is the 
preferred treatment modality for insulinomas, therefore, accurate 
localization of the tumor is mandatory (5). Herein, we present 
a case of malignant insulinoma presenting with postprandial 
hypoglycemia and discuss the differential diagnosis and possible 
mechanisms of postprandial hypoglycemia in insulinoma cases. 
Case Report
A 48-year-old woman was admitted to our department for further 
evaluation of hypoglycemia. Her symptoms, such as fatigue, 
sweating and palpitation that started four years before admission, 
were highly suggestive of hypoglycemia. Detailed history 
indicated possible hypoglycemia which begun 1-2 hours after 
meals and improved following carbohydrate ingestion. She had 
been given a diet for reactive hypoglycemia after a negative 72-
hours fasting test, which did not work, at another medical center. 
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İnsülinoma, pankreasın en sık görülen adacık hücre kaynaklı tümörüdür ve yıllık insidansı bir milyonda 4 kişi olarak tahmin edilmektedir. Her ne 
kadar tipik başvuru açlık hipoglisemisi ile olsada, literatürde postprandiyal hipoglisemi ile seyreden olgular da bulunmaktadır. Kırk sekiz yaşında 
kadın hasta hipoglisemi değerlendirilmesi amacıyla Başkent Üniversitesi Adana Hastanesi Endokrinoloji ve Metabolizma Hastalıkları Kliniği’ne 
kabul edildi. Laboratuvar verileri, postprandiyal dönemde ortaya çıkan endojen hiperinsülinemik hipoglisemiyi işaret etmekteydi. Abdominal 
kompüterize tomografi çektirildi ve pankreas distalinde 20 mm çapında kitle tespit edildi. Pankreatik kitle ile eş zamanlı saptanabilecek bir 
nesidiyoblastozisi ekarte etmek amacıyla arteryel kalsiyum uyarısı sonrası venöz örnekleme yapılmasına karar verildi. Venöz örnekleme sonrası 
hasta cerrahi bölümüne refere edildi. Patolojik incelemede, bölgesel lenf nodu metastazının eşlik ettiği düşük dereceli iyi diferansiye nöroendokrin 
tümör tespit edildi. Bu yazıda, postprandiyal hipoglisemi ile seyreden bir malin insülinoma olgusu takdim edilmiş olup, ayırıcı tanı ve insülinoma 
olgularında olası postprandiyal hipoglisemi mekanizmaları tartışılmıştır. 
Anahtar kelimeler: İnsülinoma, hipoglisemi, postprandiyal hipoglisemi
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She was not using any insulin secretagogue, and had no history 
of gastrointestinal surgery. Her family history was uneventful.
Her physical examination was normal and her body mass index 
was 27 kg/m2. Laboratory studies demonstrated an euthyroid 
state. Her morning basal serum cortisol level was 17.35 µg/dl with 
normal renal and liver function tests (Table 1). A 72-hour fasting 
test was performed and not induced hypoglycemia or symptoms 
suggestive of hypoglycemia. Then a mixed meal tolerance test 
was performed which resulted in symptomatic hypoglycemia 
with a glucose level of 19 mg/dl starting one hour following food 
ingestion. A simultaneous blood sample was withdrawn for 
further investigation, because the patient was neuroglycopenic, 
the test was ended with intravenous dextrose infusion. Her 
simultaneous insulin and c-peptide levels were 66.3 uIU/mL 
and 2.68 pmol/mL, respectively, while serum glucose level was 
found to be 19 mg/dl. These laboratory data suggested a state 
of postprandial endogenous hyperinsulinemic hypoglycemia. 
Further investigation was required. 
Abdominal computed tomography revealed a mass lesion 
measuring 20 mm in diameter at the distal pancreas which 
rapidly enhanced during arterial phase, showing similar imaging 
features with normal pancreas during portal phase (Figure 1). 
As the patient demonstrated postprandial hypoglycemia which 
was a rare presentation for insulinoma, a decision was made 
to perform arterial calcium-stimulated venous sampling for 
excluding nesidioblastosis coexisting with a pancreatic incidental 
mass. The test was performed as it was described before by 
different centers (6). During ASVS, insulin concentration was 
found to increase 33-fold after calcium stimulation in the sample 
collected from proximal splenic artery (Figure 2). This finding 
suggested that the mass which we detected at pancreatic tail on 
abdominal CT was the source of hyperinsulinemia. 
The patient underwent surgery including distal pancreatectomy 
and splenectomy. Splenic hilar lymph node dissection was 
performed due to the suspicion of nodal metastases. Intra-
operative ultrasonography detected no other mass in the rest of 
the pancreas, thus, the surgery was limited to distal pancreas 
without further resection. 
The patient was symptom-free after surgery. On pathological 
examination, the tumor cells and one of the four resected splenic 
hilar lymph nodes exhibited uniform atypical cell proliferation with 
positive immunostaining for chromogranin and synaptophysin 
(Figure 3). The Ki-67 index was <2%; necrosis and mitosis were 
not detected. The pathological findings suggested a low-grade 
well-differentiated neuroendocrine tumor with regional lymph 
node metastasis. 
Discussion 
Insulinoma is the one of the well-known causes of 
hyperinsulinemic hypoglycemia, which typically presents 
following prolonged fasting and, neuroglycopenic signs of 
hypoglycemia are its main clinical features (3). Nesidioblastosis, 
also known as noninsulinoma pancreatogenous hypoglycemia 
syndrome, in which hypoglycemia tends to occur after meals, is 
another rare cause of hyperinsulinemic hypoglycemia (7). Other 
Table 1. Documentation of the laboratory analyses of the patient on 
admission 
Findings Reference limits
Fasting glucose (mg/dl) 91 (70-110 mg/dl)
Insulin (uIU/ml) 5.6 (2.6-25 uIU/ml)
c-peptide (pmol/mL) 0.39 (0.37-1.47 pmol/mL)
Cortisol (µg/dl) 17.35 (6.20-19.4 µg/dl)
TSH (uIU/ml) 2.25 (0.4-4.67 uIU/ml)
TSH: Thyroid stimulating hormone
Figure 2. Schematic presentation of the results of Arterial Stimulation 
Venous Sampling test with calcium
Figure 3. Microscopic examination of the resected tumor. Left panel: 
Hematoxylin eosin staine section of the tumor (x100). Right panel: 
Synaptophysin stained section of the tumor (x100)
Figure 1. A-20 mm hypodense lesion in the distal portion of pancreas 
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causes of postprandial hypoglycemia are alimentary (reactive) 
hypoglycemia and functional alimentary hypoglycemia (7). Here, 
we report a case of malignant insulinoma with postprandial 
hypoglycemia, which is an unusual presentation for insulinoma. 
Our case shared various clinical, imaging and laboratory aspects 
of these hypoglycemic disorders, as we mentioned above. 
Presentation of our case with postprandial hypoglycemia and 
accompanying negative 72-hour fasting test resulted in exclusion 
of the diagnosis of insulinoma at the former medical center, thus, 
she was diagnosed as having functional alimentary hypoglycemia. 
This is the most common cause of postprandial hypoglycemia in 
which patient’s history is enough for diagnosis and no further 
laboratory evaluation is suggested. Limiting simple carbohydrates 
intake and use of acarbose when needed usually resolve the 
postprandial symptoms in cases of reactive hypoglycemia. If 
symptoms do not improve with these interventions, the patient 
deserves further evaluation, as was in our case. Since a 72-hour 
fasting test was inconclusive, a mixed meal tolerance test was 
performed which induced symptomatic hypoglycemia after the 
first hour of food ingestion and endogenous hyperinsulinemic 
hypoglycemia was diagnosed in our center. Conditions 
associated with postprandial hypoglycemia, such as alimentary 
hypoglycemia (reactive hypoglycemia), late hypoglycemia of 
occult diabetes and nesidioblastosis should be kept in mind in 
the differential diagnosis of postprandial hypoglycemic states. 
Our patient’s hypoglycemic episode which happened one 
hour following meal ingestion was not usual for the disorders 
mentioned above and necessitated further investigation. 
Although postprandial hypoglycemia is usually not attributed to 
insulinoma, there are reports suggesting that insulinomas may 
rarely present with hypoglycemic symptoms after meals. It is 
not possible to determine the exact prevalence of insulinoma 
with postprandial hypoglycemia. In a retrospective analysis of 
237 insulinoma patients, the symptoms of hypoglycemia have 
been reported in postprandial state in 6%, in whom 25% had 
a negative 72-hour fasting test (4). A negative 72-hour fasting 
test does exclude insulinoma, especially in cases presenting 
with symptoms highly suggestive of postprandial hypoglycemia. 
Patients with postprandial hypoglycemia, who do not improve 
after dietary therapy and acarbose treatment, may be selected 
for further evaluation. Objective demonstration of hypoglycemia 
is essential and insulinoma should be considered if postprandial 
hypoglycemia is proven.
There have been studies of the mechanism of hypoglycemia in 
patients with insulinoma. In contrast to normal pancreatic beta 
cells, insulinomas have been reported to express Glut-1 which is 
a peripheral cell dominant glucose transporter, and transports 
glucose into cells during basal low glucose milieu (8). This is why 
insulinomas cause fasting hypoglycemia. Pancreatic beta cells 
dominantly express Glut-2 which transports glucose into the cells 
at high glucose concentrations. On the basis of these findings, 
one of the possible explanations for insulinomas that present with 
postprandial hypoglycemia may be the predominance of Glut-2 
expression of these tumors unlike the classical insulinomas (8). 
Another explanatory approach to postprandial hypoglycemia 
in insulinomas may be through glucagon-like peptide-1 (GLP-
1), which is a gastrointestinal peptide secreted in response to 
absorbed nutrients, such as glucose and triglycerides (9). It 
stimulates postprandial insulin release in response to food intake 
via glucagon-like peptide-1 receptor (GLP-1R). Benign insulinomas 
have been reported to over-express GLP-1R, and studies which 
attempt to use these receptors for localization and targeted 
nuclear therapies of insulinomas are promising (10). Malignant 
insulinomas have been reported to express GLP-1R rarely (11). 
The pathology of the case that we report resembled a low-grade 
malignant neuroendocrine tumor which might express GLP-1 like 
benign insulinomas. Based on these assumptions, postprandial 
hypoglycemia in this case may be either due to the presence of 
Glut-2 on tumor cells or aberrant expression of GLP-1R, which 
induced the secretion of insulin from abnormal insulinoma cells. 
Nevertheless, these possible mechanisms are only mechanistic 
theories in the absence of immunostaining for Glut-2 and/or 
GLP-1R for this case. 
Conclusion
A negative 72-hour fasting test does not exclude the presence 
of insulinoma especially in patients with postprandial symptoms. 
Further evaluation is mandatory in patients whose symptoms do 
not improve after conventional treatment modalities.
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